LV15463A - 3-quinoline carboxilic acid-1,4,5,6,7,8-hexahydro-2-methyl-5-oxo-4-(2-thienyl) esters as the free fatty acid family ffar3 receptor selective ligands and syntons for creating new ligands - Google Patents

3-quinoline carboxilic acid-1,4,5,6,7,8-hexahydro-2-methyl-5-oxo-4-(2-thienyl) esters as the free fatty acid family ffar3 receptor selective ligands and syntons for creating new ligands

Info

Publication number
LV15463A
LV15463A LVP-18-50A LV180050A LV15463A LV 15463 A LV15463 A LV 15463A LV 180050 A LV180050 A LV 180050A LV 15463 A LV15463 A LV 15463A
Authority
LV
Latvia
Prior art keywords
ligands
ffar3
hexahydro
quinoline
thienyl
Prior art date
Application number
LVP-18-50A
Other languages
Latvian (lv)
Inventor
Egils Bisenieks
Ilona MANDRIKA
Ramona Petrovska
Jānis KLOVIŅŠ
Zenta KALME
Zaiga OGLE
Gunārs DUBURS
Imanta BRŪVERE
Original Assignee
Latvijas Organiskās Sintēzes Institūts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvijas Organiskās Sintēzes Institūts filed Critical Latvijas Organiskās Sintēzes Institūts
Priority to LVP-18-50A priority Critical patent/LV15463A/en
Publication of LV15463A publication Critical patent/LV15463A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to biochemistry and medicine, in particular to the 3-quinoline carboxilic acid-1,4,5,6,7,8-hexahydro-2-methyl-5-oxo-4-(2-thienyl) esters as the free fatty acid family FFAR3 receptor selective ligands which are useful in medicine for mediating lipid, cholesterol and sugar metabolism, as well as for the normalization and treatment of atherosclerotic processes.
LVP-18-50A 2018-06-11 2018-06-11 3-quinoline carboxilic acid-1,4,5,6,7,8-hexahydro-2-methyl-5-oxo-4-(2-thienyl) esters as the free fatty acid family ffar3 receptor selective ligands and syntons for creating new ligands LV15463A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LVP-18-50A LV15463A (en) 2018-06-11 2018-06-11 3-quinoline carboxilic acid-1,4,5,6,7,8-hexahydro-2-methyl-5-oxo-4-(2-thienyl) esters as the free fatty acid family ffar3 receptor selective ligands and syntons for creating new ligands

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-18-50A LV15463A (en) 2018-06-11 2018-06-11 3-quinoline carboxilic acid-1,4,5,6,7,8-hexahydro-2-methyl-5-oxo-4-(2-thienyl) esters as the free fatty acid family ffar3 receptor selective ligands and syntons for creating new ligands

Publications (1)

Publication Number Publication Date
LV15463A true LV15463A (en) 2019-12-20

Family

ID=69002167

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-18-50A LV15463A (en) 2018-06-11 2018-06-11 3-quinoline carboxilic acid-1,4,5,6,7,8-hexahydro-2-methyl-5-oxo-4-(2-thienyl) esters as the free fatty acid family ffar3 receptor selective ligands and syntons for creating new ligands

Country Status (1)

Country Link
LV (1) LV15463A (en)

Similar Documents

Publication Publication Date Title
MX2024000327A (en) Compositions and methods for delivering messenger rna.
EP4219713A3 (en) Products and compositions
PH12017501501A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
MX2022016434A (en) Glycolate oxidase inhibitors for the treatment of disease.
WO2019118638A3 (en) Rnai constructs for inhibiting pnpla3 expression
WO2016130806A3 (en) Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
MA33566B1 (en) THIOHYDANTOIDS (HETEROARYLMETHYL) SUBSTITUTED AS ANTICANCER DRUGS
MA35195B1 (en) Algal lipid compositions, methods for their preparation and their uses
BR112017004704A2 (en) compound, pharmaceutical composition, and method for treating a disease or disorder in an individual
WO2018026722A8 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MA38261A1 (en) Compounds comprising a polycyclic nucleus for use in the treatment of hepatitis c (vhc)
WO2010136900A3 (en) Methods of using krill oil to treat risk factors for metabolic disorders and obesity
MX2014014902A (en) Compositions comprising apomorphine and organic acids and uses thereof.
WO2019066577A3 (en) Composition for diagnosis and treatment of alcoholic liver disease, using change in short-chain fatty acid producing gut bacterial community
MX2019004859A (en) Combination treatments comprising administration of imidazopyrazinones.
JO3458B1 (en) 2-Amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
MA43532A (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS RELATED TO EPILEPTIC SEIZURES
CN107428652A8 (en) For treating compound, composition and the method for inflammatory disease, degenerative disease and nerve degenerative diseases
AU2017258781A1 (en) Di-substituted pyrazole compounds for the treatment of diseases
MX2016010409A (en) Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders.
WO2014144777A3 (en) Lipids that increase insulin sensitivity and methods of using the same
PH12018500035A1 (en) Nutritional compositions and methods for promoting cognitive development
LV15002A (en) Substituted heterocycle [(2-carboxy or -methoxycarbonyl)phenylcarbamoyl-methyl (or trimethylen)]-pyridinium or isoquinolinium bromides as hydroxycarboxylic acid receptor (hca2) family novel class of ligands
MY179419A (en) Chocolate
WO2016068453A8 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component